Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of repotrectinib in frail and/or elderly patients with ROS1-rearranged advanced NSCLC
2023-509073-23-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Intercommunal de Toulon-La Seyne-sur-Mer
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of repotrectinib in Non-small cell lung cancer (NSCLC), sponsored by Centre Hospitalier Intercommunal de Toulon-La Seyne-sur-Mer. Primary endpoint: ORR by BICR (primary). Planned start Jul 2024; status: authorised.
02
Drugs
repotrectinib
03
Conditions
Non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509073-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509073-23-00.